VIAF

Virtual International Authority File

Search

Leader 00000nz a2200037n 45 0
001 WKP|Q90397473 (VIAF cluster) (Authority/Source Record)
003 WKP
005 20241121000159.0
008 241121nneanz||abbn n and d
035 ‎‡a (WKP)Q90397473‏
024 ‎‡a 0000-0002-1576-4420‏ ‎‡2 orcid‏
035 ‎‡a (OCoLC)Q90397473‏
100 0 ‎‡a ইভান জে অ্যান্ডারসন‏ ‎‡9 bn‏
400 0 ‎‡a Evan J. Anderson‏ ‎‡c researcher (ORCID 0000-0002-1576-4420)‏ ‎‡9 en‏
400 0 ‎‡a Evan J Anderson‏ ‎‡c wetenschapper‏ ‎‡9 nl‏
670 ‎‡a Author's 1621. Acute Cardiovascular Events Among Adults Hospitalized with Influenza, FluSurv-NET, 2010–2018‏
670 ‎‡a Author's 1714Influenza antiviral agent use among adults hospitalized with community-acquired pneumonia.‏
670 ‎‡a Author's 2212. Burden of Community-Acquired Pneumonia Attributable to Co-morbid Conditions in Adults‏
670 ‎‡a Author's 2280. Antibiotic Exposure Does Not Impact Serological Responses to Rotavirus Vaccination‏
670 ‎‡a Author's 2314. Burden of Respiratory Syncytial Virus (RSV) Infection Among Hospitalized Older Adults and Those with Underlying Chronic Obstructive Pulmonary Disease (COPD) or Congestive Heart Failure (CHF)‏
670 ‎‡a Author's 2494. Influenza B Hospitalizations Are Associated With Mortality in Children, FluSurv-NET, 2011–2017‏
670 ‎‡a Author's 2498. Association of Increasing Age With Hospitalization Rates, Clinical Presentation, and Outcomes Among Older Adults Hospitalized With Influenza—US Influenza Hospitalization Surveillance Network (FluSurv-NET)‏
670 ‎‡a Author's 2741. Seasonal Influenza Vaccine Timing in Children and Adults Hospitalized with Influenza in the United States, FluSurv-NET, 2013–2017‏
670 ‎‡a Author's 2797. Rates of Respiratory Syncytial Virus (RSV) Infection among Hospitalized Adults by Congestive Heart Failure Status—United States, 2015–2017‏
670 ‎‡a Author's 354. Evidence of Aspergillosis Among Patients With Influenza-Associated Hospitalizations—United States, 2005–2017‏
670 ‎‡a Author's 720. Respiratory and Nonrespiratory Complications Among Patients Hospitalized with Influenza, FluSurv-NET, 2016–2017‏
670 ‎‡a Author's 746. Characteristics of Respiratory Syncytial Virus (RSV) Infection Among Hospitalized Adults, United States, 2014–2017‏
670 ‎‡a Author's 780Clinical Characteristics And Outcomes among Children with Neurological Disorders Hospitalized with Community-acquired Pneumonia‏
670 ‎‡a Author's 780Clinical Characteristics And Outcomes among Children with Neurological Disorders Hospitalized with Community-acquired Pneumonia (CAP) in the Etiology of Pneumonia in the Community (EPIC) Study.‏
670 ‎‡a Author's 781Rhinovirus in Children Hospitalized with Community Acquired Pneumonia: Insights from the Centers for Disease Control and Prevention‏
670 ‎‡a Author's 781Rhinovirus in Children Hospitalized with Community Acquired Pneumonia: Insights from the Centers for Disease Control and Prevention (CDC) Etiology of Pneumonia in the Community (EPIC) Study.‏
670 ‎‡a Author's 846. Postnatally Acquired Zika Virus (ZIKV) Infection in Infants and Young Children in Guatemala: Serologic and Neurodevelopmental (ND) Evaluation‏
670 ‎‡a Author's 898. Influenza Vaccination Reduces Risk of Severe Outcomes among Adults Hospitalized with Influenza A(H1N1)pdm09, FluSurv-NET, 2013–2018‏
670 ‎‡a Author's 94. Pneumonia Severity Scores Poorly Predict Severe Outcomes Among Adults Hospitalized with Influenza‏
670 ‎‡a Author's A rational approach to the management of ventricular shunt infections‏
670 ‎‡a Author's Acute Cardiovascular Events Associated With Influenza in Hospitalized Adults: A Cross-sectional Study‏
670 ‎‡a Author's Age-Related Differences in Hospitalization Rates, Clinical Presentation, and Outcomes Among Older Adults Hospitalized With Influenza-U.S. Influenza Hospitalization Surveillance Network (FluSurv-NET)‏
670 ‎‡a Author's Alterations in the Human Plasma Lipidome in Response to Tularemia Vaccination‏
670 ‎‡a Author's An mRNA Vaccine against SARS-CoV-2 - Preliminary Report‏
670 ‎‡a Author's Antibiotic Prescribing for Adults Hospitalized in the Etiology of Pneumonia in the Community Study‏
670 ‎‡a Author's Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19‏
670 ‎‡a Author's Association Between Hospitalization With Community-Acquired Laboratory-Confirmed Influenza Pneumonia and Prior Receipt of Influenza Vaccination‏
670 ‎‡a Author's Baseline Levels of Influenza-Specific B Cells and T Cell Responses Modulate Human Immune Responses to Swine Variant Influenza A/H3N2 Vaccine‏
670 ‎‡a Author's Benefit of Early Initiation of Influenza Antiviral Treatment to Pregnant Women Hospitalized With Laboratory-Confirmed Influenza‏
670 ‎‡a Author's Blastomycosis in Children: A Study of 14 Cases‏
670 ‎‡a Author's Burden of Severe Respiratory Syncytial Virus Disease Among 33-35 Weeks' Gestational Age Infants Born During Multiple Respiratory Syncytial Virus Seasons.‏
670 ‎‡a Author's Causes of In-hospital and Post discharge Mortality Among Patients Hospitalized with Laboratory-Confirmed Influenza, Influenza Hospitalization Surveillance Network, 2014–2015.‏
670 ‎‡a Author's Characteristics and Maternal and Birth Outcomes of Hospitalized Pregnant Women with Laboratory-Confirmed COVID-19 - COVID-NET, 13 States, March 1-August 22, 2020‏
670 ‎‡a Author's Clinical characteristics and genotypes of rotavirus in adults‏
670 ‎‡a Author's Clinical Features and Outcomes of Immunocompromised Children Hospitalized With Laboratory-Confirmed Influenza in the United States, 2011-2015‏
670 ‎‡a Author's Clinical Features of Human Metapneumovirus-Associated Community-Acquired Pneumonia Hospitalizations‏
670 ‎‡a Author's Community-Acquired Pneumonia Hospitalization among Children with Neurologic Disorders‏
670 ‎‡a Author's Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults‏
670 ‎‡a Author's Community-acquired pneumonia requiring hospitalization among U.S. children‏
670 ‎‡a Author's Community-acquired Pneumonia Visualized on Computed Tomography but Not Chest X-Ray: Pathogens, Severity, and Clinical Outcomes‏
670 ‎‡a Author's Correction: Effects of Chronologic Age and Young Child Exposure on Respiratory Syncytial Virus Disease among US Preterm Infants Born at 32 to 35 Weeks Gestation‏
670 ‎‡a Author's COVID-19-Associated Hospitalizations Among Health Care Personnel - COVID-NET, 13 States, March 1-May 31, 2020‏
670 ‎‡a Author's COVID-19 Investigational Treatments in Use Among Hospitalized Patients Identified Through the US Coronavirus Disease 2019-Associated Hospitalization Surveillance Network, March 1-June 30, 2020‏
670 ‎‡a Author's COVID-19 Vaccines Have Moved Out of Neutral, but Still Gearing Up in Children‏
670 ‎‡a Author's Dengue Virus and Yellow Fever Virus Detection Using Reverse Transcription-Insulated Isothermal PCR and Comparison with Real-Time RT-PCR‏
670 ‎‡a Author's Does Influenza Vaccination Modify Influenza Severity? Data on Older Adults Hospitalized With Influenza During the 2012-2013 Season in the United States‏
670 ‎‡a Author's Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants‏
670 ‎‡a Author's Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants‏
670 ‎‡a Author's Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination‏
670 ‎‡a Author's Duration of Cellular and Humoral Responses after Quadrivalent Human Papillomavirus Vaccination in Healthy Female Adults with or without Prior Type 16 and/or 18 Exposure‏
670 ‎‡a Author's Ebola or Not? Evaluating the Ill Traveler From Ebola-Affected Countries in West Africa‏
670 ‎‡a Author's Echocardiography in pediatric infective endocarditis.‏
670 ‎‡a Author's Effect of Concomitant Antibiotic and Vaccine Administration on Serologic Responses to Rotavirus Vaccine‏
670 ‎‡a Author's Effectiveness of Palivizumab in High-risk Infants and Children: A Propensity Score Weighted Regression Analysis‏
670 ‎‡a Author's Effectiveness of β-Lactam Monotherapy vs Macrolide Combination Therapy for Children Hospitalized With Pneumonia.‏
670 ‎‡a Author's Effects of Chronologic Age and Young Child Exposure on Respiratory Syncytial Virus Disease among US Preterm Infants Born at 32 to 35 Weeks Gestation.‏
670 ‎‡a Author's Effects of Influenza Vaccination in the United States during the 2017-2018 Influenza Season‏
670 ‎‡a Author's Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase‏
670 ‎‡a Author's Estimated Burden of Community-Onset Respiratory Syncytial Virus-Associated Hospitalizations Among Children Aged <2 Years in the United States, 2014-15‏
670 ‎‡a Author's Gram-Positive Diplococci in a Cerebrospinal Fluid Gram Stain‏
670 ‎‡a Author's High-risk adenovirus-infected pediatric allogeneic hematopoietic progenitor cell transplant recipients and preemptive cidofovir therapy‏
670 ‎‡a Author's Hospitalization Is an Underutilized Opportunity to Vaccinate for Influenza‏
670 ‎‡a Author's Hospitalization Rates and Characteristics of Children Aged <18 Years Hospitalized with Laboratory-Confirmed COVID-19 - COVID-NET, 14 States, March 1-July 25, 2020‏
670 ‎‡a Author's Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 - COVID-NET, 14 States, March 1-30, 2020‏
670 ‎‡a Author's Identification of adenoviruses in specimens from high-risk pediatric stem cell transplant recipients and controls‏
670 ‎‡a Author's Identification of Bacterial and Viral Codetections With Mycoplasma pneumoniae Using the TaqMan Array Card in Patients Hospitalized With Community-Acquired Pneumonia‏
670 ‎‡a Author's Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and older‏
670 ‎‡a Author's Impact of pregnancy on observed sex disparities among adults hospitalized with laboratory-confirmed influenza, FluSurv-NET, 2010-2012.‏
670 ‎‡a Author's Impact of rotavirus vaccination on hospital-acquired rotavirus gastroenteritis in children‏
670 ‎‡a Author's In-Hospital Deaths Among Adults With Community-Acquired Pneumonia‏
670 ‎‡a Author's In-Hospital Pneumococcal Polysaccharide Vaccination Is Associated With Detection of Pneumococcal Vaccine Serotypes in Adults Hospitalized for Community-Acquired Pneumonia‏
670 ‎‡a Author's Increased Antiviral Treatment Among Hospitalized Children and Adults With Laboratory-Confirmed Influenza, 2010-2015‏
670 ‎‡a Author's Indirect protection and indirect measures of protection from rotavirus in adults‏
670 ‎‡a Author's Indirect protection of adults from rotavirus by pediatric rotavirus vaccination‏
670 ‎‡a Author's Influence of Antibiotics on the Detection of Bacteria by Culture-Based and Culture-Independent Diagnostic Tests in Patients Hospitalized With Community-Acquired Pneumonia‏
670 ‎‡a Author's Influenza-Related Hospitalizations and Poverty Levels - United States, 2010-2012.‏
670 ‎‡a Author's Influenza vaccination modifies disease severity among community-dwelling adults hospitalized with influenza‏
670 ‎‡a Author's Insurance Status and the Risk of Severe Respiratory Syncytial Virus Disease in United States Preterm Infants Born at 32-35 Weeks Gestational Age.‏
670 ‎‡a Author's Intensive care unit admission rates for respiratory syncytial virus infection as a function of age in preterm infants born at 32-35-week gestation and not receiving immunoprophylaxis‏
670 ‎‡a Author's Intent to Vaccinate SARS-CoV-2 Infected Children in US Households: A Survey‏
670 ‎‡a Author's Interim Analysis of Risk Factors for Severe Outcomes among a Cohort of Hospitalized Adults Identified through the U.S. Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET)‏
670 ‎‡a Author's LB17. Age-Related Differences in Influenza Type/Subtype Among Patients Hospitalized with Influenza, FluSurv-NET—2017–2018‏
670 ‎‡a Author's LB19. Patterns of Influenza A Hospitalizations by Subtype and Age in the United States, FluSurv-NET, 2018–2019‏
670 ‎‡a Author's Low Admission Plasma Gelsolin Concentrations Identify Community-acquired Pneumonia Patients at High Risk for Severe Outcomes‏
670 ‎‡a Author's Missed Opportunities for Rotavirus Vaccination‏
670 ‎‡a Author's Molecular Detection and Characterization of Mycoplasma pneumoniae Among Patients Hospitalized With Community-Acquired Pneumonia in the United States‏
670 ‎‡a Author's Molecular epidemiology of norovirus in children and the elderly in Atlanta, Georgia, United States‏
670 ‎‡a Author's Mupirocin for Staphylococcus aureus Decolonization of Infants in Neonatal Intensive Care Units‏
670 ‎‡a Author's Neonatal and Pediatric Candidemia: Results From Population-Based Active Laboratory Surveillance in Four US Locations, 2009-2015.‏
670 ‎‡a Author's Obesity not associated with severity among hospitalized adults with seasonal influenza virus infection‏
670 ‎‡a Author's Oseltamivir Use Among Children and Adults Hospitalized With Community-Acquired Pneumonia‏
670 ‎‡a Author's Outcomes of immunocompromised adults hospitalized with laboratory-confirmed influenza in the United States, 2011-2015‏
670 ‎‡a Author's Parainfluenza Virus Types 1-3 Infections Among Children and Adults Hospitalized with Community-Acquired Pneumonia‏
670 ‎‡a Author's Pediatric Dental Clinic-Associated Outbreak of Mycobacterium abscessus Infection‏
670 ‎‡a Author's Persistence of Immunogenicity of a Purified Inactivated Zika Virus Vaccine Candidate in Healthy Adults: 2 Years of Follow-up Compared With Natural Infection‏
670 ‎‡a Author's Plasmablast, Memory B Cell, CD4+ T Cell, and Circulating Follicular Helper T Cell Responses to a Non-Replicating Modified Vaccinia Ankara Vaccine‏
670 ‎‡a Author's Pneumococcal and Legionella Urinary Antigen Tests in Community-acquired Pneumonia: Prospective Evaluation of Indications for Testing‏
670 ‎‡a Author's Pneumococcal Community-Acquired Pneumonia Detected by Serotype-Specific Urinary Antigen Detection Assays‏
670 ‎‡a Author's Polymicrobial ventriculitis involving Pseudomonas fulva‏
670 ‎‡a Author's Predicting Severe Pneumonia Outcomes in Children‏
670 ‎‡a Author's Prevalence and Characteristics of Human Metapneumovirus Infection Among Hospitalized Children at High Risk for Severe Lower Respiratory Tract Infection‏
670 ‎‡a Author's Prevalence of Staphylococcus aureus and Use of Antistaphylococcal Therapy in Children Hospitalized with Pneumonia‏
670 ‎‡a Author's Prevalence, Risk Factors, and Outcomes of Bacteremic Pneumonia in Children‏
670 ‎‡a Author's Procalcitonin Accurately Identifies Hospitalized Children With Low Risk of Bacterial Community-Acquired Pneumonia.‏
670 ‎‡a Author's Procalcitonin as a Marker of Etiology in Adults Hospitalized with Community-Acquired Pneumonia‏
670 ‎‡a Author's Procalcitonin as an Early Marker of the Need for Invasive Respiratory or Vasopressor Support in Adults With Community-Acquired Pneumonia‏
670 ‎‡a Author's Protecting the Community through Child Vaccination.‏
670 ‎‡a Author's Proteomic Analysis of Human Immune Responses to Live-Attenuated Tularemia Vaccine‏
670 ‎‡a Author's Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients‏
670 ‎‡a Author's Relationship Between Body Mass Index and Outcomes Among Hospitalized Patients With Community-Acquired Pneumonia‏
670 ‎‡a Author's Respiratory and Nonrespiratory Diagnoses Associated With Influenza in Hospitalized Adults‏
670 ‎‡a Author's Respiratory syncytial virus disease in preterm infants in the U.S. born at 32-35 weeks gestation not receiving immunoprophylaxis.‏
670 ‎‡a Author's Respiratory syncytial virus hospitalizations in US preterm infants after the 2014 change in immunoprophylaxis guidance by the American Academy of Pediatrics‏
670 ‎‡a Author's Rhinovirus Viremia in Patients Hospitalized With Community-Acquired Pneumonia‏
670 ‎‡a Author's Risk Factors for COVID-19-associated hospitalization: COVID-19-Associated Hospitalization Surveillance Network and Behavioral Risk Factor Surveillance System‏
670 ‎‡a Author's Risk Factors for Intensive Care Unit Admission and In-hospital Mortality among Hospitalized Adults Identified through the U.S. Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET)‏
670 ‎‡a Author's Risk scoring tool to predict respiratory syncytial virus hospitalisation in premature infants‏
670 ‎‡a Author's Rotavirus and Norovirus in Pediatric Healthcare-Associated Gastroenteritis‏
670 ‎‡a Author's Rotavirus in adults requiring hospitalization‏
670 ‎‡a Author's Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults‏
670 ‎‡a Author's Safety and immunogenicity of unadjuvanted subvirion monovalent inactivated influenza H3N2 variant (H3N2v) vaccine in children and adolescents‏
670 ‎‡a Author's SENTINEL1: An Observational Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis‏
670 ‎‡a Author's SENTINEL1: Two-Season Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis‏
670 ‎‡a Author's Serological Response to Influenza Vaccination Among Adults Hospitalized with Community Acquired Pneumonia‏
670 ‎‡a Author's Serology Enhances Molecular Diagnosis of Respiratory Virus Infections Other than Influenza in Children and Adults Hospitalized with Community-Acquired Pneumonia‏
670 ‎‡a Author's Sirolimus-associated pericardial effusion with cardiac tamponade and interstitial pneumonitis in a hematopoietic stem cell transplant recipient‏
670 ‎‡a Author's Social Determinants of Influenza Hospitalization in the United States‏
670 ‎‡a Author's Spatial and temporal clustering of patients hospitalized with laboratory-confirmed influenza in the United States‏
670 ‎‡a Author's Staphylococcus aureus Community-acquired Pneumonia: Prevalence, Clinical Characteristics, and Outcomes‏
670 ‎‡a Author's Statin Use and Hospital Length of Stay Among Adults Hospitalized With Community-acquired Pneumonia.‏
670 ‎‡a Author's Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans‏
670 ‎‡a Author's Systems Vaccinology for a Live Attenuated Tularemia Vaccine Reveals Unique Transcriptional Signatures That Predict Humoral and Cellular Immune Responses‏
670 ‎‡a Author's The development and kinetics of functional antibody-dependent cell-mediated cytotoxicity (ADCC) to SARS-CoV-2 spike protein‏
670 ‎‡a Author's The etiology and impact of co-infections in children hospitalized with community-acquired pneumonia‏
670 ‎‡a Author's The Importance of Advancing SARS-CoV-2 Vaccines in Children‏
670 ‎‡a Author's The Residual Vaccine-preventable Burden of Rotavirus Disease.‏
670 ‎‡a Author's Transcriptomic and Metabolic Responses to a Live-Attenuated Francisella tularensis Vaccine‏
670 ‎‡a Author's Use of Multiple Imputation to Estimate the Proportion of Respiratory Virus Detections Among Patients Hospitalized With Community-Acquired Pneumonia.‏
670 ‎‡a Author's Warp Speed for COVID-19 Vaccines: Why are Children Stuck in Neutral?‏
909 ‎‡a (orcid) 0000000215764420‏ ‎‡9 1‏
919 ‎‡a statinuseandhospitallengthofstayamongadultshospitalizedwithcommunityacquiredpneumonia‏ ‎‡A Statin Use and Hospital Length of Stay Among Adults Hospitalized With Community-acquired Pneumonia.‏ ‎‡9 1‏
919 ‎‡a staphylococcusaureuscommunityacquiredpneumoniaprevalenceclinicalcharacteristicsandoutcomes‏ ‎‡A Staphylococcus aureus Community-acquired Pneumonia: Prevalence, Clinical Characteristics, and Outcomes‏ ‎‡9 1‏
919 ‎‡a spatialandtemporalclusteringofpatientshospitalizedwithlaboratoryconfirmedinfluenzaintheunitedstates‏ ‎‡A Spatial and temporal clustering of patients hospitalized with laboratory-confirmed influenza in the United States‏ ‎‡9 1‏
919 ‎‡a socialdeterminantsofinfluenzahospitalizationintheunitedstates‏ ‎‡A Social Determinants of Influenza Hospitalization in the United States‏ ‎‡9 1‏
919 ‎‡a etiologyandimpactofcoinfectionsinchildrenhospitalizedwithcommunityacquiredpneumonia‏ ‎‡A The etiology and impact of co-infections in children hospitalized with community-acquired pneumonia‏ ‎‡9 1‏
919 ‎‡a importanceofadvancingsarscov2vaccinesinchildren‏ ‎‡A The Importance of Advancing SARS-CoV-2 Vaccines in Children‏ ‎‡9 1‏
919 ‎‡a sirolimusassociatedpericardialeffusionwithcardiactamponadeandinterstitialpneumonitisinahematopoieticstemcelltransplantrecipient‏ ‎‡A Sirolimus-associated pericardial effusion with cardiac tamponade and interstitial pneumonitis in a hematopoietic stem cell transplant recipient‏ ‎‡9 1‏
919 ‎‡a serologyenhancesmoleculardiagnosisofrespiratoryvirusinfectionsotherthaninfluenzainchildrenandadultshospitalizedwithcommunityacquiredpneumonia‏ ‎‡A Serology Enhances Molecular Diagnosis of Respiratory Virus Infections Other than Influenza in Children and Adults Hospitalized with Community-Acquired Pneumonia‏ ‎‡9 1‏
919 ‎‡a serologicalresponsetoinfluenzavaccinationamongadultshospitalizedwithcommunityacquiredpneumonia‏ ‎‡A Serological Response to Influenza Vaccination Among Adults Hospitalized with Community Acquired Pneumonia‏ ‎‡9 1‏
919 ‎‡a sentinel12seasonstudyofrespiratorysyncytialvirushospitalizationsamongusinfantsbornat29to35weeksgestationalagenotreceivingimmunoprophylaxis‏ ‎‡A SENTINEL1: Two-Season Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis‏ ‎‡9 1‏
919 ‎‡a sentinel1anobservationalstudyofrespiratorysyncytialvirushospitalizationsamongusinfantsbornat29to35weeksgestationalagenotreceivingimmunoprophylaxis‏ ‎‡A SENTINEL1: An Observational Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis‏ ‎‡9 1‏
919 ‎‡a residualvaccinepreventableburdenofrotavirusdisease‏ ‎‡A The Residual Vaccine-preventable Burden of Rotavirus Disease.‏ ‎‡9 1‏
919 ‎‡a transcriptomicandmetabolicresponsestoaliveattenuatedfrancisellatularensisvaccine‏ ‎‡A Transcriptomic and Metabolic Responses to a Live-Attenuated Francisella tularensis Vaccine‏ ‎‡9 1‏
919 ‎‡a useofmultipleimputationtoestimatetheproportionofrespiratoryvirusdetectionsamongpatientshospitalizedwithcommunityacquiredpneumonia‏ ‎‡A Use of Multiple Imputation to Estimate the Proportion of Respiratory Virus Detections Among Patients Hospitalized With Community-Acquired Pneumonia.‏ ‎‡9 1‏
919 ‎‡a safetyandimmunogenicityofunadjuvantedsubvirionmonovalentinactivatedinfluenzah3n2varianth3n2vvaccineinchildrenandadolescents‏ ‎‡A Safety and immunogenicity of unadjuvanted subvirion monovalent inactivated influenza H3N2 variant (H3N2v) vaccine in children and adolescents‏ ‎‡9 1‏
919 ‎‡a safetyandimmunogenicityofsarscov2mrna1273vaccineinolderadults‏ ‎‡A Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults‏ ‎‡9 1‏
919 ‎‡a rotavirusinadultsrequiringhospitalization‏ ‎‡A Rotavirus in adults requiring hospitalization‏ ‎‡9 1‏
919 ‎‡a rotavirusandnorovirusinpediatrichealthcareassociatedgastroenteritis‏ ‎‡A Rotavirus and Norovirus in Pediatric Healthcare-Associated Gastroenteritis‏ ‎‡9 1‏
919 ‎‡a riskscoringtooltopredictrespiratorysyncytialvirushospitalisationinprematureinfants‏ ‎‡A Risk scoring tool to predict respiratory syncytial virus hospitalisation in premature infants‏ ‎‡9 1‏
919 ‎‡a riskfactorsforintensivecareunitadmissionandinhospitalmortalityamonghospitalizedadultsidentifiedthroughtheuscoronavirusdisease2019covid19associatedhospitalizationsurveillancenetworkcovidnet‏ ‎‡A Risk Factors for Intensive Care Unit Admission and In-hospital Mortality among Hospitalized Adults Identified through the U.S. Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET)‏ ‎‡9 1‏
919 ‎‡a riskfactorsforcovid19associatedhospitalizationcovid19associatedhospitalizationsurveillancenetworkandbehavioralriskfactorsurveillancesystem‏ ‎‡A Risk Factors for COVID-19-associated hospitalization: COVID-19-Associated Hospitalization Surveillance Network and Behavioral Risk Factor Surveillance System‏ ‎‡9 1‏
919 ‎‡a rhinovirusviremiainpatientshospitalizedwithcommunityacquiredpneumonia‏ ‎‡A Rhinovirus Viremia in Patients Hospitalized With Community-Acquired Pneumonia‏ ‎‡9 1‏
919 ‎‡a respiratorysyncytialvirushospitalizationsinuspreterminfantsafterthe2014changeinimmunoprophylaxisguidancebytheamericanacademyofpediatrics‏ ‎‡A Respiratory syncytial virus hospitalizations in US preterm infants after the 2014 change in immunoprophylaxis guidance by the American Academy of Pediatrics‏ ‎‡9 1‏
919 ‎‡a respiratorysyncytialvirusdiseaseinpreterminfantsintheusbornat3235weeksgestationnotreceivingimmunoprophylaxis‏ ‎‡A Respiratory syncytial virus disease in preterm infants in the U.S. born at 32-35 weeks gestation not receiving immunoprophylaxis.‏ ‎‡9 1‏
919 ‎‡a respiratoryandnonrespiratorydiagnosesassociatedwithinfluenzainhospitalizedadults‏ ‎‡A Respiratory and Nonrespiratory Diagnoses Associated With Influenza in Hospitalized Adults‏ ‎‡9 1‏
919 ‎‡a warpspeedforcovid19vaccineswhyarechildrenstuckinneutral‏ ‎‡A Warp Speed for COVID-19 Vaccines: Why are Children Stuck in Neutral?‏ ‎‡9 1‏
919 ‎‡a relationshipbetweenbodymassindexandoutcomesamonghospitalizedpatientswithcommunityacquiredpneumonia‏ ‎‡A Relationship Between Body Mass Index and Outcomes Among Hospitalized Patients With Community-Acquired Pneumonia‏ ‎‡9 1‏
919 ‎‡a rapidgenerationofneutralizingantibodyresponsesincovid19patients‏ ‎‡A Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients‏ ‎‡9 1‏
919 ‎‡a proteomicanalysisofhumanimmuneresponsestoliveattenuatedtularemiavaccine‏ ‎‡A Proteomic Analysis of Human Immune Responses to Live-Attenuated Tularemia Vaccine‏ ‎‡9 1‏
919 ‎‡a protectingthecommunitythroughchildvaccination‏ ‎‡A Protecting the Community through Child Vaccination.‏ ‎‡9 1‏
919 ‎‡a procalcitoninasanearlymarkeroftheneedforinvasiverespiratoryorvasopressorsupportinadultswithcommunityacquiredpneumonia‏ ‎‡A Procalcitonin as an Early Marker of the Need for Invasive Respiratory or Vasopressor Support in Adults With Community-Acquired Pneumonia‏ ‎‡9 1‏
919 ‎‡a procalcitoninasamarkerofetiologyinadultshospitalizedwithcommunityacquiredpneumonia‏ ‎‡A Procalcitonin as a Marker of Etiology in Adults Hospitalized with Community-Acquired Pneumonia‏ ‎‡9 1‏
919 ‎‡a procalcitoninaccuratelyidentifieshospitalizedchildrenwithlowriskofbacterialcommunityacquiredpneumonia‏ ‎‡A Procalcitonin Accurately Identifies Hospitalized Children With Low Risk of Bacterial Community-Acquired Pneumonia.‏ ‎‡9 1‏
919 ‎‡a prevalenceriskfactorsandoutcomesofbacteremicpneumoniainchildren‏ ‎‡A Prevalence, Risk Factors, and Outcomes of Bacteremic Pneumonia in Children‏ ‎‡9 1‏
919 ‎‡a prevalenceofstaphylococcusaureusanduseofantistaphylococcaltherapyinchildrenhospitalizedwithpneumonia‏ ‎‡A Prevalence of Staphylococcus aureus and Use of Antistaphylococcal Therapy in Children Hospitalized with Pneumonia‏ ‎‡9 1‏
919 ‎‡a prevalenceandcharacteristicsofhumanmetapneumovirusinfectionamonghospitalizedchildrenathighriskforseverelowerrespiratorytractinfection‏ ‎‡A Prevalence and Characteristics of Human Metapneumovirus Infection Among Hospitalized Children at High Risk for Severe Lower Respiratory Tract Infection‏ ‎‡9 1‏
919 ‎‡a predictingseverepneumoniaoutcomesinchildren‏ ‎‡A Predicting Severe Pneumonia Outcomes in Children‏ ‎‡9 1‏
919 ‎‡a polymicrobialventriculitisinvolvingpseudomonasfulva‏ ‎‡A Polymicrobial ventriculitis involving Pseudomonas fulva‏ ‎‡9 1‏
919 ‎‡a pneumococcalcommunityacquiredpneumoniadetectedbyserotypespecificurinaryantigendetectionassays‏ ‎‡A Pneumococcal Community-Acquired Pneumonia Detected by Serotype-Specific Urinary Antigen Detection Assays‏ ‎‡9 1‏
919 ‎‡a pneumococcalandlegionellaurinaryantigentestsincommunityacquiredpneumoniaprospectiveevaluationofindicationsfortesting‏ ‎‡A Pneumococcal and Legionella Urinary Antigen Tests in Community-acquired Pneumonia: Prospective Evaluation of Indications for Testing‏ ‎‡9 1‏
919 ‎‡a plasmablastmemorybcellcd4+tcellandcirculatingfollicularhelpertcellresponsestoanonreplicatingmodifiedvacciniaankaravaccine‏ ‎‡A Plasmablast, Memory B Cell, CD4+ T Cell, and Circulating Follicular Helper T Cell Responses to a Non-Replicating Modified Vaccinia Ankara Vaccine‏ ‎‡9 1‏
919 ‎‡a persistenceofimmunogenicityofapurifiedinactivatedzikavirusvaccinecandidateinhealthyadults2yearsoffollowupcomparedwithnaturalinfection‏ ‎‡A Persistence of Immunogenicity of a Purified Inactivated Zika Virus Vaccine Candidate in Healthy Adults: 2 Years of Follow-up Compared With Natural Infection‏ ‎‡9 1‏
919 ‎‡a pediatricdentalclinicassociatedoutbreakofmycobacteriumabscessusinfection‏ ‎‡A Pediatric Dental Clinic-Associated Outbreak of Mycobacterium abscessus Infection‏ ‎‡9 1‏
919 ‎‡a parainfluenzavirustypes13infectionsamongchildrenandadultshospitalizedwithcommunityacquiredpneumonia‏ ‎‡A Parainfluenza Virus Types 1-3 Infections Among Children and Adults Hospitalized with Community-Acquired Pneumonia‏ ‎‡9 1‏
919 ‎‡a outcomesofimmunocompromisedadultshospitalizedwithlaboratoryconfirmedinfluenzaintheunitedstates2011‏ ‎‡A Outcomes of immunocompromised adults hospitalized with laboratory-confirmed influenza in the United States, 2011-2015‏ ‎‡9 1‏
919 ‎‡a oseltamiviruseamongchildrenandadultshospitalizedwithcommunityacquiredpneumonia‏ ‎‡A Oseltamivir Use Among Children and Adults Hospitalized With Community-Acquired Pneumonia‏ ‎‡9 1‏
919 ‎‡a obesitynotassociatedwithseverityamonghospitalizedadultswithseasonalinfluenzavirusinfection‏ ‎‡A Obesity not associated with severity among hospitalized adults with seasonal influenza virus infection‏ ‎‡9 1‏
919 ‎‡a neonatalandpediatriccandidemiaresultsfrompopulationbasedactivelaboratorysurveillancein4uslocations2009‏ ‎‡A Neonatal and Pediatric Candidemia: Results From Population-Based Active Laboratory Surveillance in Four US Locations, 2009-2015.‏ ‎‡9 1‏
919 ‎‡a mupirocinforstaphylococcusaureusdecolonizationofinfantsinneonatalintensivecareunits‏ ‎‡A Mupirocin for Staphylococcus aureus Decolonization of Infants in Neonatal Intensive Care Units‏ ‎‡9 1‏
919 ‎‡a molecularepidemiologyofnorovirusinchildrenandtheelderlyinatlantageorgiaunitedstates‏ ‎‡A Molecular epidemiology of norovirus in children and the elderly in Atlanta, Georgia, United States‏ ‎‡9 1‏
919 ‎‡a moleculardetectionandcharacterizationofmycoplasmapneumoniaeamongpatientshospitalizedwithcommunityacquiredpneumoniaintheunitedstates‏ ‎‡A Molecular Detection and Characterization of Mycoplasma pneumoniae Among Patients Hospitalized With Community-Acquired Pneumonia in the United States‏ ‎‡9 1‏
919 ‎‡a missedopportunitiesforrotavirusvaccination‏ ‎‡A Missed Opportunities for Rotavirus Vaccination‏ ‎‡9 1‏
919 ‎‡a lowadmissionplasmagelsolinconcentrationsidentifycommunityacquiredpneumoniapatientsathighriskforsevereoutcomes‏ ‎‡A Low Admission Plasma Gelsolin Concentrations Identify Community-acquired Pneumonia Patients at High Risk for Severe Outcomes‏ ‎‡9 1‏
919 ‎‡a lb19patternsofinfluenzaahospitalizationsbysubtypeandageintheunitedstatesflusurvnet2018‏ ‎‡A LB19. Patterns of Influenza A Hospitalizations by Subtype and Age in the United States, FluSurv-NET, 2018–2019‏ ‎‡9 1‏
919 ‎‡a lb17agerelateddifferencesininfluenzatypesubtypeamongpatientshospitalizedwithinfluenzaflusurvnet2017‏ ‎‡A LB17. Age-Related Differences in Influenza Type/Subtype Among Patients Hospitalized with Influenza, FluSurv-NET—2017–2018‏ ‎‡9 1‏
919 ‎‡a interimanalysisofriskfactorsforsevereoutcomesamongacohortofhospitalizedadultsidentifiedthroughtheuscoronavirusdisease2019covid19associatedhospitalizationsurveillancenetworkcovidnet‏ ‎‡A Interim Analysis of Risk Factors for Severe Outcomes among a Cohort of Hospitalized Adults Identified through the U.S. Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET)‏ ‎‡9 1‏
919 ‎‡a intenttovaccinatesarscov2infectedchildreninushouseholdsasurvey‏ ‎‡A Intent to Vaccinate SARS-CoV-2 Infected Children in US Households: A Survey‏ ‎‡9 1‏
919 ‎‡a intensivecareunitadmissionratesforrespiratorysyncytialvirusinfectionasafunctionofageinpreterminfantsbornat3235weekgestationandnotreceivingimmunoprophylaxis‏ ‎‡A Intensive care unit admission rates for respiratory syncytial virus infection as a function of age in preterm infants born at 32-35-week gestation and not receiving immunoprophylaxis‏ ‎‡9 1‏
919 ‎‡a insurancestatusandtheriskofsevererespiratorysyncytialvirusdiseaseinunitedstatespreterminfantsbornat3235weeksgestationalage‏ ‎‡A Insurance Status and the Risk of Severe Respiratory Syncytial Virus Disease in United States Preterm Infants Born at 32-35 Weeks Gestational Age.‏ ‎‡9 1‏
919 ‎‡a influenzavaccinationmodifiesdiseaseseverityamongcommunitydwellingadultshospitalizedwithinfluenza‏ ‎‡A Influenza vaccination modifies disease severity among community-dwelling adults hospitalized with influenza‏ ‎‡9 1‏
919 ‎‡a influenzarelatedhospitalizationsandpovertylevelsunitedstates2010‏ ‎‡A Influenza-Related Hospitalizations and Poverty Levels - United States, 2010-2012.‏ ‎‡9 1‏
919 ‎‡a influenceofantibioticsonthedetectionofbacteriabyculturebasedandcultureindependentdiagnostictestsinpatientshospitalizedwithcommunityacquiredpneumonia‏ ‎‡A Influence of Antibiotics on the Detection of Bacteria by Culture-Based and Culture-Independent Diagnostic Tests in Patients Hospitalized With Community-Acquired Pneumonia‏ ‎‡9 1‏
919 ‎‡a indirectprotectionofadultsfromrotavirusbypediatricrotavirusvaccination‏ ‎‡A Indirect protection of adults from rotavirus by pediatric rotavirus vaccination‏ ‎‡9 1‏
919 ‎‡a indirectprotectionandindirectmeasuresofprotectionfromrotavirusinadults‏ ‎‡A Indirect protection and indirect measures of protection from rotavirus in adults‏ ‎‡9 1‏
919 ‎‡a increasedantiviraltreatmentamonghospitalizedchildrenandadultswithlaboratoryconfirmedinfluenza2010‏ ‎‡A Increased Antiviral Treatment Among Hospitalized Children and Adults With Laboratory-Confirmed Influenza, 2010-2015‏ ‎‡9 1‏
919 ‎‡a inhospitalpneumococcalpolysaccharidevaccinationisassociatedwithdetectionofpneumococcalvaccineserotypesinadultshospitalizedforcommunityacquiredpneumonia‏ ‎‡A In-Hospital Pneumococcal Polysaccharide Vaccination Is Associated With Detection of Pneumococcal Vaccine Serotypes in Adults Hospitalized for Community-Acquired Pneumonia‏ ‎‡9 1‏
919 ‎‡a inhospitaldeathsamongadultswithcommunityacquiredpneumonia‏ ‎‡A In-Hospital Deaths Among Adults With Community-Acquired Pneumonia‏ ‎‡9 1‏
919 ‎‡a impactofrotavirusvaccinationonhospitalacquiredrotavirusgastroenteritisinchildren‏ ‎‡A Impact of rotavirus vaccination on hospital-acquired rotavirus gastroenteritis in children‏ ‎‡9 1‏
919 ‎‡a impactofpregnancyonobservedsexdisparitiesamongadultshospitalizedwithlaboratoryconfirmedinfluenzaflusurvnet2010‏ ‎‡A Impact of pregnancy on observed sex disparities among adults hospitalized with laboratory-confirmed influenza, FluSurv-NET, 2010-2012.‏ ‎‡9 1‏
919 ‎‡a immunogenicityandsafetyofdifferentdoseschedulesandantigendosesofanmf59adjuvantedh7n9vaccineinhealthyadultsaged65yearsandolder‏ ‎‡A Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and older‏ ‎‡9 1‏
919 ‎‡a identificationofbacterialandviralcodetectionswithmycoplasmapneumoniaeusingthetaqmanarraycardinpatientshospitalizedwithcommunityacquiredpneumonia‏ ‎‡A Identification of Bacterial and Viral Codetections With Mycoplasma pneumoniae Using the TaqMan Array Card in Patients Hospitalized With Community-Acquired Pneumonia‏ ‎‡9 1‏
919 ‎‡a identificationofadenovirusesinspecimensfromhighriskpediatricstemcelltransplantrecipientsandcontrols‏ ‎‡A Identification of adenoviruses in specimens from high-risk pediatric stem cell transplant recipients and controls‏ ‎‡9 1‏
919 ‎‡a hospitalizationratesandcharacteristicsofpatientshospitalizedwithlaboratoryconfirmedcoronavirusdisease2019covidnet14statesmarch130‏ ‎‡A Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 - COVID-NET, 14 States, March 1-30, 2020‏ ‎‡9 1‏
919 ‎‡a hospitalizationratesandcharacteristicsofchildrenaged18yearshospitalizedwithlaboratoryconfirmedcovid19covidnet14statesmarch1july25‏ ‎‡A Hospitalization Rates and Characteristics of Children Aged <18 Years Hospitalized with Laboratory-Confirmed COVID-19 - COVID-NET, 14 States, March 1-July 25, 2020‏ ‎‡9 1‏
919 ‎‡a hospitalizationisanunderutilizedopportunitytovaccinateforinfluenza‏ ‎‡A Hospitalization Is an Underutilized Opportunity to Vaccinate for Influenza‏ ‎‡9 1‏
919 ‎‡a highriskadenovirusinfectedpediatricallogeneichematopoieticprogenitorcelltransplantrecipientsandpreemptivecidofovirtherapy‏ ‎‡A High-risk adenovirus-infected pediatric allogeneic hematopoietic progenitor cell transplant recipients and preemptive cidofovir therapy‏ ‎‡9 1‏
919 ‎‡a grampositivediplococciinacerebrospinalfluidgramstain‏ ‎‡A Gram-Positive Diplococci in a Cerebrospinal Fluid Gram Stain‏ ‎‡9 1‏
919 ‎‡a estimatedburdenofcommunityonsetrespiratorysyncytialvirusassociatedhospitalizationsamongchildrenaged2yearsintheunitedstates201415‏ ‎‡A Estimated Burden of Community-Onset Respiratory Syncytial Virus-Associated Hospitalizations Among Children Aged <2 Years in the United States, 2014-15‏ ‎‡9 1‏
919 ‎‡a efficacyofthemrna1273sarscov2vaccineatcompletionofblindedphase‏ ‎‡A Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase‏ ‎‡9 1‏
919 ‎‡a effectsofinfluenzavaccinationintheunitedstatesduringthe20172018influenzaseason‏ ‎‡A Effects of Influenza Vaccination in the United States during the 2017-2018 Influenza Season‏ ‎‡9 1‏
919 ‎‡a effectsofchronologicageandyoungchildexposureonrespiratorysyncytialvirusdiseaseamonguspreterminfantsbornat32to35weeksgestation‏ ‎‡A Effects of Chronologic Age and Young Child Exposure on Respiratory Syncytial Virus Disease among US Preterm Infants Born at 32 to 35 Weeks Gestation.‏ ‎‡9 1‏
919 ‎‡a effectivenessofβlactammonotherapyvsmacrolidecombinationtherapyforchildrenhospitalizedwithpneumonia‏ ‎‡A Effectiveness of β-Lactam Monotherapy vs Macrolide Combination Therapy for Children Hospitalized With Pneumonia.‏ ‎‡9 1‏
919 ‎‡a effectivenessofpalivizumabinhighriskinfantsandchildrenapropensityscoreweightedregressionanalysis‏ ‎‡A Effectiveness of Palivizumab in High-risk Infants and Children: A Propensity Score Weighted Regression Analysis‏ ‎‡9 1‏
919 ‎‡a effectofconcomitantantibioticandvaccineadministrationonserologicresponsestorotavirusvaccine‏ ‎‡A Effect of Concomitant Antibiotic and Vaccine Administration on Serologic Responses to Rotavirus Vaccine‏ ‎‡9 1‏
919 ‎‡a echocardiographyinpediatricinfectiveendocarditis‏ ‎‡A Echocardiography in pediatric infective endocarditis.‏ ‎‡9 1‏
919 ‎‡a ebolaornotevaluatingtheilltravelerfromebolaaffectedcountriesinwestafrica‏ ‎‡A Ebola or Not? Evaluating the Ill Traveler From Ebola-Affected Countries in West Africa‏ ‎‡9 1‏
919 ‎‡a durationofcellularandhumoralresponsesafterquadrivalenthumanpapillomavirusvaccinationinhealthyfemaleadultswithorwithoutpriortype16andor18exposure‏ ‎‡A Duration of Cellular and Humoral Responses after Quadrivalent Human Papillomavirus Vaccination in Healthy Female Adults with or without Prior Type 16 and/or 18 Exposure‏ ‎‡9 1‏
919 ‎‡a durabilityofresponsesaftersarscov2mrna1273vaccination‏ ‎‡A Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination‏ ‎‡9 1‏
919 ‎‡a durabilityofmrna1273vaccineinducedantibodiesagainstsarscov2variants‏ ‎‡A Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants‏ ‎‡9 1‏
919 ‎‡a durabilityofmrna1273inducedantibodiesagainstsarscov2variants‏ ‎‡A Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants‏ ‎‡9 1‏
919 ‎‡a doesinfluenzavaccinationmodifyinfluenzaseveritydataonolderadultshospitalizedwithinfluenzaduringthe20122013seasonintheunitedstates‏ ‎‡A Does Influenza Vaccination Modify Influenza Severity? Data on Older Adults Hospitalized With Influenza During the 2012-2013 Season in the United States‏ ‎‡9 1‏
919 ‎‡a denguevirusandyellowfevervirusdetectionusingreversetranscriptioninsulatedisothermalpcrandcomparisonwithrealtimertpcr‏ ‎‡A Dengue Virus and Yellow Fever Virus Detection Using Reverse Transcription-Insulated Isothermal PCR and Comparison with Real-Time RT-PCR‏ ‎‡9 1‏
919 ‎‡a covid19vaccineshavemovedoutofneutralbutstillgearingupinchildren‏ ‎‡A COVID-19 Vaccines Have Moved Out of Neutral, but Still Gearing Up in Children‏ ‎‡9 1‏
919 ‎‡a covid19investigationaltreatmentsinuseamonghospitalizedpatientsidentifiedthroughtheuscoronavirusdisease2019associatedhospitalizationsurveillancenetworkmarch1june30‏ ‎‡A COVID-19 Investigational Treatments in Use Among Hospitalized Patients Identified Through the US Coronavirus Disease 2019-Associated Hospitalization Surveillance Network, March 1-June 30, 2020‏ ‎‡9 1‏
919 ‎‡a covid19associatedhospitalizationsamonghealthcarepersonnelcovidnet13statesmarch1may31‏ ‎‡A COVID-19-Associated Hospitalizations Among Health Care Personnel - COVID-NET, 13 States, March 1-May 31, 2020‏ ‎‡9 1‏
919 ‎‡a correctioneffectsofchronologicageandyoungchildexposureonrespiratorysyncytialvirusdiseaseamonguspreterminfantsbornat32to35weeksgestation‏ ‎‡A Correction: Effects of Chronologic Age and Young Child Exposure on Respiratory Syncytial Virus Disease among US Preterm Infants Born at 32 to 35 Weeks Gestation‏ ‎‡9 1‏
919 ‎‡a communityacquiredpneumoniavisualizedoncomputedtomographybutnotchest10raypathogensseverityandclinicaloutcomes‏ ‎‡A Community-acquired Pneumonia Visualized on Computed Tomography but Not Chest X-Ray: Pathogens, Severity, and Clinical Outcomes‏ ‎‡9 1‏
919 ‎‡a communityacquiredpneumoniarequiringhospitalizationamonguschildren‏ ‎‡A Community-acquired pneumonia requiring hospitalization among U.S. children‏ ‎‡9 1‏
919 ‎‡a communityacquiredpneumoniarequiringhospitalizationamongusadults‏ ‎‡A Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults‏ ‎‡9 1‏
919 ‎‡a communityacquiredpneumoniahospitalizationamongchildrenwithneurologicdisorders‏ ‎‡A Community-Acquired Pneumonia Hospitalization among Children with Neurologic Disorders‏ ‎‡9 1‏
919 ‎‡a clinicalfeaturesofhumanmetapneumovirusassociatedcommunityacquiredpneumoniahospitalizations‏ ‎‡A Clinical Features of Human Metapneumovirus-Associated Community-Acquired Pneumonia Hospitalizations‏ ‎‡9 1‏
919 ‎‡a clinicalfeaturesandoutcomesofimmunocompromisedchildrenhospitalizedwithlaboratoryconfirmedinfluenzaintheunitedstates2011‏ ‎‡A Clinical Features and Outcomes of Immunocompromised Children Hospitalized With Laboratory-Confirmed Influenza in the United States, 2011-2015‏ ‎‡9 1‏
919 ‎‡a clinicalcharacteristicsandgenotypesofrotavirusinadults‏ ‎‡A Clinical characteristics and genotypes of rotavirus in adults‏ ‎‡9 1‏
919 ‎‡a characteristicsandmaternalandbirthoutcomesofhospitalizedpregnantwomenwithlaboratoryconfirmedcovid19covidnet13statesmarch1august22‏ ‎‡A Characteristics and Maternal and Birth Outcomes of Hospitalized Pregnant Women with Laboratory-Confirmed COVID-19 - COVID-NET, 13 States, March 1-August 22, 2020‏ ‎‡9 1‏
919 ‎‡a causesofinhospitalandpostdischargemortalityamongpatientshospitalizedwithlaboratoryconfirmedinfluenzainfluenzahospitalizationsurveillancenetwork2014‏ ‎‡A Causes of In-hospital and Post discharge Mortality Among Patients Hospitalized with Laboratory-Confirmed Influenza, Influenza Hospitalization Surveillance Network, 2014–2015.‏ ‎‡9 1‏
919 ‎‡a burdenofsevererespiratorysyncytialvirusdiseaseamong3335weeksgestationalageinfantsbornduringmultiplerespiratorysyncytialvirusseasons‏ ‎‡A Burden of Severe Respiratory Syncytial Virus Disease Among 33-35 Weeks' Gestational Age Infants Born During Multiple Respiratory Syncytial Virus Seasons.‏ ‎‡9 1‏
919 ‎‡a blastomycosisinchildrenastudyof14cases‏ ‎‡A Blastomycosis in Children: A Study of 14 Cases‏ ‎‡9 1‏
919 ‎‡a benefitofearlyinitiationofinfluenzaantiviraltreatmenttopregnantwomenhospitalizedwithlaboratoryconfirmedinfluenza‏ ‎‡A Benefit of Early Initiation of Influenza Antiviral Treatment to Pregnant Women Hospitalized With Laboratory-Confirmed Influenza‏ ‎‡9 1‏
919 ‎‡a baselinelevelsofinfluenzaspecificbcellsandtcellresponsesmodulatehumanimmuneresponsestoswinevariantinfluenzaah3n2vaccine‏ ‎‡A Baseline Levels of Influenza-Specific B Cells and T Cell Responses Modulate Human Immune Responses to Swine Variant Influenza A/H3N2 Vaccine‏ ‎‡9 1‏
919 ‎‡a associationbetweenhospitalizationwithcommunityacquiredlaboratoryconfirmedinfluenzapneumoniaandpriorreceiptofinfluenzavaccination‏ ‎‡A Association Between Hospitalization With Community-Acquired Laboratory-Confirmed Influenza Pneumonia and Prior Receipt of Influenza Vaccination‏ ‎‡9 1‏
919 ‎‡a antibodypersistencethrough6monthsafterthe2doseofmrna1273vaccineforcovid19‏ ‎‡A Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19‏ ‎‡9 1‏
919 ‎‡a antibioticprescribingforadultshospitalizedintheetiologyofpneumoniainthecommunitystudy‏ ‎‡A Antibiotic Prescribing for Adults Hospitalized in the Etiology of Pneumonia in the Community Study‏ ‎‡9 1‏
919 ‎‡a mrnavaccineagainstsarscov2preliminaryreport‏ ‎‡A An mRNA Vaccine against SARS-CoV-2 - Preliminary Report‏ ‎‡9 1‏
919 ‎‡a alterationsinthehumanplasmalipidomeinresponsetotularemiavaccination‏ ‎‡A Alterations in the Human Plasma Lipidome in Response to Tularemia Vaccination‏ ‎‡9 1‏
919 ‎‡a agerelateddifferencesinhospitalizationratesclinicalpresentationandoutcomesamongolderadultshospitalizedwithinfluenzausinfluenzahospitalizationsurveillancenetworkflusurvnet‏ ‎‡A Age-Related Differences in Hospitalization Rates, Clinical Presentation, and Outcomes Among Older Adults Hospitalized With Influenza-U.S. Influenza Hospitalization Surveillance Network (FluSurv-NET)‏ ‎‡9 1‏
919 ‎‡a acutecardiovasculareventsassociatedwithinfluenzainhospitalizedadultsacrosssectionalstudy‏ ‎‡A Acute Cardiovascular Events Associated With Influenza in Hospitalized Adults: A Cross-sectional Study‏ ‎‡9 1‏
919 ‎‡a rationalapproachtothemanagementofventricularshuntinfections‏ ‎‡A A rational approach to the management of ventricular shunt infections‏ ‎‡9 1‏
919 ‎‡a 94pneumoniaseverityscorespoorlypredictsevereoutcomesamongadultshospitalizedwithinfluenza‏ ‎‡A 94. Pneumonia Severity Scores Poorly Predict Severe Outcomes Among Adults Hospitalized with Influenza‏ ‎‡9 1‏
919 ‎‡a 898influenzavaccinationreducesriskofsevereoutcomesamongadultshospitalizedwithinfluenzaah1n1pdm09flusurvnet2013‏ ‎‡A 898. Influenza Vaccination Reduces Risk of Severe Outcomes among Adults Hospitalized with Influenza A(H1N1)pdm09, FluSurv-NET, 2013–2018‏ ‎‡9 1‏
919 ‎‡a 846postnatallyacquiredzikaviruszikvinfectionininfantsandyoungchildreninguatemalaserologicandneurodevelopmentalndevaluation‏ ‎‡A 846. Postnatally Acquired Zika Virus (ZIKV) Infection in Infants and Young Children in Guatemala: Serologic and Neurodevelopmental (ND) Evaluation‏ ‎‡9 1‏
919 ‎‡a 781rhinovirusinchildrenhospitalizedwithcommunityacquiredpneumoniainsightsfromthecentersfordiseasecontrolandpreventioncdcetiologyofpneumoniainthecommunityepicstudy‏ ‎‡A 781Rhinovirus in Children Hospitalized with Community Acquired Pneumonia: Insights from the Centers for Disease Control and Prevention (CDC) Etiology of Pneumonia in the Community (EPIC) Study.‏ ‎‡9 1‏
919 ‎‡a 781rhinovirusinchildrenhospitalizedwithcommunityacquiredpneumoniainsightsfromthecentersfordiseasecontrolandprevention‏ ‎‡A 781Rhinovirus in Children Hospitalized with Community Acquired Pneumonia: Insights from the Centers for Disease Control and Prevention‏ ‎‡9 1‏
919 ‎‡a 780clinicalcharacteristicsandoutcomesamongchildrenwithneurologicaldisordershospitalizedwithcommunityacquiredpneumoniacapintheetiologyofpneumoniainthecommunityepicstudy‏ ‎‡A 780Clinical Characteristics And Outcomes among Children with Neurological Disorders Hospitalized with Community-acquired Pneumonia (CAP) in the Etiology of Pneumonia in the Community (EPIC) Study.‏ ‎‡9 1‏
919 ‎‡a 780clinicalcharacteristicsandoutcomesamongchildrenwithneurologicaldisordershospitalizedwithcommunityacquiredpneumonia‏ ‎‡A 780Clinical Characteristics And Outcomes among Children with Neurological Disorders Hospitalized with Community-acquired Pneumonia‏ ‎‡9 1‏
919 ‎‡a 746characteristicsofrespiratorysyncytialvirusrsvinfectionamonghospitalizedadultsunitedstates2014‏ ‎‡A 746. Characteristics of Respiratory Syncytial Virus (RSV) Infection Among Hospitalized Adults, United States, 2014–2017‏ ‎‡9 1‏
919 ‎‡a 720respiratoryandnonrespiratorycomplicationsamongpatientshospitalizedwithinfluenzaflusurvnet2016‏ ‎‡A 720. Respiratory and Nonrespiratory Complications Among Patients Hospitalized with Influenza, FluSurv-NET, 2016–2017‏ ‎‡9 1‏
919 ‎‡a 354evidenceofaspergillosisamongpatientswithinfluenzaassociatedhospitalizationsunitedstates2005‏ ‎‡A 354. Evidence of Aspergillosis Among Patients With Influenza-Associated Hospitalizations—United States, 2005–2017‏ ‎‡9 1‏
919 ‎‡a 2797ratesofrespiratorysyncytialvirusrsvinfectionamonghospitalizedadultsbycongestiveheartfailurestatusunitedstates2015‏ ‎‡A 2797. Rates of Respiratory Syncytial Virus (RSV) Infection among Hospitalized Adults by Congestive Heart Failure Status—United States, 2015–2017‏ ‎‡9 1‏
919 ‎‡a 2741seasonalinfluenzavaccinetiminginchildrenandadultshospitalizedwithinfluenzaintheunitedstatesflusurvnet2013‏ ‎‡A 2741. Seasonal Influenza Vaccine Timing in Children and Adults Hospitalized with Influenza in the United States, FluSurv-NET, 2013–2017‏ ‎‡9 1‏
919 ‎‡a 2498associationofincreasingagewithhospitalizationratesclinicalpresentationandoutcomesamongolderadultshospitalizedwithinfluenzausinfluenzahospitalizationsurveillancenetworkflusurvnet‏ ‎‡A 2498. Association of Increasing Age With Hospitalization Rates, Clinical Presentation, and Outcomes Among Older Adults Hospitalized With Influenza—US Influenza Hospitalization Surveillance Network (FluSurv-NET)‏ ‎‡9 1‏
919 ‎‡a 2494influenzabhospitalizationsareassociatedwithmortalityinchildrenflusurvnet2011‏ ‎‡A 2494. Influenza B Hospitalizations Are Associated With Mortality in Children, FluSurv-NET, 2011–2017‏ ‎‡9 1‏
919 ‎‡a 2314burdenofrespiratorysyncytialvirusrsvinfectionamonghospitalizedolderadultsandthosewithunderlyingchronicobstructivepulmonarydiseasecopdorcongestiveheartfailurechf‏ ‎‡A 2314. Burden of Respiratory Syncytial Virus (RSV) Infection Among Hospitalized Older Adults and Those with Underlying Chronic Obstructive Pulmonary Disease (COPD) or Congestive Heart Failure (CHF)‏ ‎‡9 1‏
919 ‎‡a 2280antibioticexposuredoesnotimpactserologicalresponsestorotavirusvaccination‏ ‎‡A 2280. Antibiotic Exposure Does Not Impact Serological Responses to Rotavirus Vaccination‏ ‎‡9 1‏
919 ‎‡a 2212burdenofcommunityacquiredpneumoniaattributabletocomorbidconditionsinadults‏ ‎‡A 2212. Burden of Community-Acquired Pneumonia Attributable to Co-morbid Conditions in Adults‏ ‎‡9 1‏
919 ‎‡a 1714influenzaantiviralagentuseamongadultshospitalizedwithcommunityacquiredpneumonia‏ ‎‡A 1714Influenza antiviral agent use among adults hospitalized with community-acquired pneumonia.‏ ‎‡9 1‏
919 ‎‡a 1621acutecardiovasculareventsamongadultshospitalizedwithinfluenzaflusurvnet2010‏ ‎‡A 1621. Acute Cardiovascular Events Among Adults Hospitalized with Influenza, FluSurv-NET, 2010–2018‏ ‎‡9 1‏
919 ‎‡a developmentandkineticsoffunctionalantibodydependentcellmediatedcytotoxicityadcctosarscov2spikeprotein‏ ‎‡A The development and kinetics of functional antibody-dependent cell-mediated cytotoxicity (ADCC) to SARS-CoV-2 spike protein‏ ‎‡9 1‏
919 ‎‡a systemsvaccinologyforaliveattenuatedtularemiavaccinerevealsuniquetranscriptionalsignaturesthatpredicthumoralandcellularimmuneresponses‏ ‎‡A Systems Vaccinology for a Live Attenuated Tularemia Vaccine Reveals Unique Transcriptional Signatures That Predict Humoral and Cellular Immune Responses‏ ‎‡9 1‏
919 ‎‡a systemsbiologicalassessmentofimmunitytomildversusseverecovid19infectioninhumans‏ ‎‡A Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans‏ ‎‡9 1‏
943 ‎‡a 201x‏ ‎‡A 2015‏ ‎‡9 17‏
943 ‎‡a 202x‏ ‎‡A 2020‏ ‎‡9 5‏
996 ‎‡2 LC|no2017101939‏
996 ‎‡2 DNB|127076417‏
996 ‎‡2 NTA|132987724‏
996 ‎‡2 CAOONL|ncf11200741‏
996 ‎‡2 RERO|A024115401‏
996 ‎‡2 SUDOC|13250636X‏
996 ‎‡2 W2Z|1688713701802‏
996 ‎‡2 LC|n 88058044‏
996 ‎‡2 LC|no2023133558‏
996 ‎‡2 NDL|00511706‏
996 ‎‡2 N6I|vtls001278262‏
996 ‎‡2 NTA|12669656X‏
996 ‎‡2 J9U|987012508961905171‏
996 ‎‡2 ISNI|0000000022301526‏
996 ‎‡2 DNB|1216116628‏
996 ‎‡2 LC|n 91071525‏
996 ‎‡2 ISNI|000000042538491X‏
996 ‎‡2 SUDOC|18615867X‏
996 ‎‡2 LC|n 2013029049‏
996 ‎‡2 NUKAT|n 97014732‏
996 ‎‡2 SIMACOB|47446627‏
996 ‎‡2 CAOONL|ncf10000407‏
996 ‎‡2 RERO|A002928247‏
996 ‎‡2 LC|no2024092502‏
996 ‎‡2 BIBSYS|90754759‏
996 ‎‡2 RERO|A002928149‏
996 ‎‡2 J9U|987007323641805171‏
996 ‎‡2 LC|n 89649540‏
996 ‎‡2 LC|no 94011590‏
996 ‎‡2 ISNI|0000000032996210‏
996 ‎‡2 NUKAT|n 01019211‏
996 ‎‡2 NTA|074499629‏
996 ‎‡2 SUDOC|248544403‏
996 ‎‡2 SUDOC|185920977‏
996 ‎‡2 LC|no2020015730‏
996 ‎‡2 LC|n 83143558‏
996 ‎‡2 J9U|987007325819405171‏
996 ‎‡2 LC|n 91048722‏
996 ‎‡2 LC|n 2012067763‏
996 ‎‡2 BIBSYS|90679016‏
996 ‎‡2 BIBSYS|90252683‏
996 ‎‡2 LC|no2009176089‏
996 ‎‡2 LC|n 92040509‏
996 ‎‡2 LC|no2022118376‏
996 ‎‡2 RERO|A002928147‏
996 ‎‡2 NLA|000036025502‏
996 ‎‡2 LC|n 86130888‏
996 ‎‡2 SUDOC|08160937X‏
996 ‎‡2 BIBSYS|1688713701802‏
996 ‎‡2 NUKAT|n 2004086963‏
996 ‎‡2 RERO|A002928148‏
996 ‎‡2 LC|no2015059671‏
996 ‎‡2 NTA|079658431‏
996 ‎‡2 BNCHL|10000000000000000188572‏
996 ‎‡2 NII|DA06589156‏
996 ‎‡2 LC|nb2001030533‏
996 ‎‡2 CAOONL|ncf11640773‏
996 ‎‡2 J9U|987007423000005171‏
996 ‎‡2 BIBSYS|90571648‏
996 ‎‡2 ISNI|0000000032195130‏
996 ‎‡2 BIBSYS|40516‏
996 ‎‡2 LC|no2023081018‏
996 ‎‡2 NUKAT|n 2007114071‏
996 ‎‡2 BIBSYS|90658660‏
996 ‎‡2 LC|no2009187615‏
997 ‎‡a 0 0 lived 0 0‏ ‎‡9 1‏